Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth’s second low-dose HRT

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Wyeth plans to launch low-dose Premarin (.45 mg estrogens) this summer along with the recently approved low-dose PremPro (.45 mg estrogens/1.5 mg medroxyprogesterone). FDA cleared the Premarin formulation April 25; low-dose PremPro was approved March 12 (1Pharmaceutical Approvals Monthly April 1, In Brief). The product's estrogen content is 28% less than the standard .625 mg dose, which Wyeth says allows for "better individualization of therapy, particularly for new patients." The firm hopes that the low-dose products will allay concerns stemming from the Women's Health Initiative stud

You may also be interested in...

Wyeth’s lowest Prempro formulation

Wyeth will launch its lowest dose of Prempro (0.3 mg conjugated estrogens/1.5 mg medroxyprogesterone) late in the year following validation of manufacturing procedures. FDA approved the lower dose hormone replacement therapy June 4 for treatment of moderate to severe menopausal vasomotor symptoms and for postmenopausal osteoporosis prevention. The approval follows FDA's post-Women's Health Initiative recommendations that patients receive the lowest dose of HRT for the shortest amount of time (1Pharmaceutical Approvals Monthly May 1, 2003, In Brief). The agency simultaneously approved Prempro 0.45 /1.5 for the osteoporosis indication. Previously, only higher Prempro doses (0.625/2.5 and 0.625/5) were approved for osteoporosis preventio

Barr low-dose Cenestin "not approvable"

Barr's 0.45 mg formulation of its plant-derived hormone therapy Cenestin receives "not approvable" letter, firm announces June 3. The 0.45 mg synthetic conjugated estrogens tablet is under review for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Cenestin is currently available in 0.3 mg, 0.625 mg, 0.9 mg and 1.25 mg tablets, but the 0.3 mg dosage strength is indicated only for the treatment of vulvar and vaginal atrophy. The agency's decision follows recent approvals of low-dose formulations of Wyeth's Premarin and PremPro (1Pharmaceutical Approvals Monthly May 1, 2003, In Brief). Safety concerns from the Women's Health Initiative study have led to increased interest in lower dose hormone therapies. Barr plans to meet with FDA "as soon as possible"...

Low-dose Prempro approval

Wyeth plans early summer 2003 launch for low-dose formulation of Prempro (0.45 mg conjugated estrogens/1.5 mg medroxyprogesterone). The March 12 approval is based on the 2,805-patient HOPE study, which found the lower dose to be as effective as the 0.625 mg/2.5 mg dose in treating vasomotor symptoms and vaginal atrophy. The approval gives Wyeth the first positive news in hormone therapy since the Women's Health Initiative Prempro study arm was halted in July 2002 due to an increased risk of breast cancer and adverse cardiovascular outcomes. The firm is also pursuing a 0.3/1.5 formulation, with approval expected as early as Septembe





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts